ID   ABC3B_HUMAN             Reviewed;         382 AA.
AC   Q9UH17; B0QYD2; O95618; Q20WL1; Q5IFJ4; Q7Z2N3; Q7Z6D6; Q9UE74;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   28-JUN-2023, entry version 180.
DE   RecName: Full=DNA dC->dU-editing enzyme APOBEC-3B;
DE            Short=A3B;
DE            EC=3.5.4.38;
DE   AltName: Full=Phorbolin-1-related protein;
DE   AltName: Full=Phorbolin-2/3;
GN   Name=APOBEC3B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT LYS-146, AND INDUCTION.
RC   TISSUE=Keratinocyte;
RX   PubMed=10469298; DOI=10.1046/j.1523-1747.1999.00682.x;
RA   Madsen P.P., Anant S., Rasmussen H.H., Gromov P., Vorum H., Dumanski J.P.,
RA   Tommerup N., Collins J.E., Wright C.L., Dunham I., Macginnitie A.J.,
RA   Davidson N.O., Celis J.E.;
RT   "Psoriasis upregulated phorbolin-1 shares structural but not functional
RT   similarity to the mRNA-editing protein apobec-1.";
RL   J. Invest. Dermatol. 113:162-169(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=16060832; DOI=10.1089/aid.2005.21.611;
RA   Rose K.M., Marin M., Kozak S.L., Kabat D.;
RT   "Regulated production and anti-HIV type 1 activities of cytidine deaminases
RT   APOBEC3B, 3F, and 3G.";
RL   AIDS Res. Hum. Retroviruses 21:611-619(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANTS GLU-62 AND
RP   LYS-146.
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M.,
RA   Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C.,
RA   Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E.,
RA   Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C.,
RA   Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G.,
RA   Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V.,
RA   Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M.,
RA   Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E.,
RA   Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F.,
RA   Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M.,
RA   Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A.,
RA   Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D.,
RA   Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y.,
RA   Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S.,
RA   Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E.,
RA   Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A.,
RA   Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L.,
RA   Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P.,
RA   Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P.,
RA   Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q.,
RA   Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J.,
RA   Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J.,
RA   Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D.,
RA   Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T.,
RA   Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P.,
RA   Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K.,
RA   Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L.,
RA   McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J.,
RA   Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E.,
RA   Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P.,
RA   Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y.,
RA   Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT LYS-146.
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   GENE FAMILY ORGANIZATION, TISSUE SPECIFICITY, RNA-BINDING, ZINC-BINDING,
RP   AND INTERACTION WITH APOBEC3G.
RX   PubMed=11863358; DOI=10.1006/geno.2002.6718;
RA   Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J.,
RA   Navaratnam N.;
RT   "An anthropoid-specific locus of orphan C to U RNA-editing enzymes on
RT   chromosome 22.";
RL   Genomics 79:285-296(2002).
RN   [7]
RP   REVIEW ON APOBEC FAMILIES.
RX   PubMed=12683974; DOI=10.1016/s0168-9525(03)00054-4;
RA   Wedekind J.E., Dance G.S.C., Sowden M.P., Smith H.C.;
RT   "Messenger RNA editing in mammals: new members of the APOBEC family seeking
RT   roles in the family business.";
RL   Trends Genet. 19:207-216(2003).
RN   [8]
RP   FUNCTION IN HIV-1 INFECTIVITY.
RX   PubMed=12859895; DOI=10.1016/s0092-8674(03)00515-4;
RA   Mariani R., Chen D., Schroefelbauer B., Navarro F., Koenig R., Bollman B.,
RA   Muenk C., Nymark-McMahon H., Landau N.R.;
RT   "Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.";
RL   Cell 114:21-31(2003).
RN   [9]
RP   FUNCTION IN SIV RESTRICTION.
RX   PubMed=15466872; DOI=10.1074/jbc.m408802200;
RA   Yu Q., Chen D., Koenig R., Mariani R., Unutmaz D., Landau N.R.;
RT   "APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency
RT   virus replication.";
RL   J. Biol. Chem. 279:53379-53386(2004).
RN   [10]
RP   FUNCTION IN RETROTRANSPOSITION.
RX   PubMed=16527742; DOI=10.1016/j.cub.2006.01.031;
RA   Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I., Landau N.R.,
RA   Weitzman M.D.;
RT   "APOBEC3A is a potent inhibitor of adeno-associated virus and
RT   retrotransposons.";
RL   Curr. Biol. 16:480-485(2006).
RN   [11]
RP   DOMAIN CMP/DCMP DEAMINASE.
RX   PubMed=17020885; DOI=10.1074/jbc.m604980200;
RA   Hakata Y., Landau N.R.;
RT   "Reversed functional organization of mouse and human APOBEC3 cytidine
RT   deaminase domains.";
RL   J. Biol. Chem. 281:36624-36631(2006).
RN   [12]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16699599; DOI=10.1371/journal.ppat.0020041;
RA   Wichroski M.J., Robb G.B., Rana T.M.;
RT   "Human retroviral host restriction factors APOBEC3G and APOBEC3F localize
RT   to mRNA processing bodies.";
RL   PLoS Pathog. 2:E41-E41(2006).
RN   [13]
RP   REVIEW.
RX   PubMed=18304004; DOI=10.1146/annurev.immunol.26.021607.090350;
RA   Chiu Y.L., Greene W.C.;
RT   "The APOBEC3 cytidine deaminases: an innate defensive network opposing
RT   exogenous retroviruses and endogenous retroelements.";
RL   Annu. Rev. Immunol. 26:317-353(2008).
RN   [14]
RP   REVIEW ON FUNCTION IN HBV RESTRICTION.
RX   PubMed=18448976; DOI=10.1097/qco.0b013e3282fe1bb2;
RA   Bonvin M., Greeve J.;
RT   "Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine deaminases
RT   as effectors in innate immunity against the hepatitis B virus.";
RL   Curr. Opin. Infect. Dis. 21:298-303(2008).
RN   [15]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18667511; DOI=10.1128/jvi.02471-07;
RA   Stenglein M.D., Matsuo H., Harris R.S.;
RT   "Two regions within the amino-terminal half of APOBEC3G cooperate to
RT   determine cytoplasmic localization.";
RL   J. Virol. 82:9591-9599(2008).
RN   [16]
RP   TISSUE SPECIFICITY.
RX   PubMed=20308164; DOI=10.1093/nar/gkq174;
RA   Refsland E.W., Stenglein M.D., Shindo K., Albin J.S., Brown W.L.,
RA   Harris R.S.;
RT   "Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes
RT   and tissues: implications for HIV-1 restriction.";
RL   Nucleic Acids Res. 38:4274-4284(2010).
RN   [17]
RP   FUNCTION IN RETROTRANSPOSITION.
RX   PubMed=20062055; DOI=10.1038/nsmb.1744;
RA   Stenglein M.D., Burns M.B., Li M., Lengyel J., Harris R.S.;
RT   "APOBEC3 proteins mediate the clearance of foreign DNA from human cells.";
RL   Nat. Struct. Mol. Biol. 17:222-229(2010).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21835787; DOI=10.1128/jvi.05238-11;
RA   Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L.,
RA   Brown W.L., Harris R.S.;
RT   "Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a
RT   conserved capacity to restrict Vif-deficient HIV-1.";
RL   J. Virol. 85:11220-11234(2011).
RN   [19]
RP   REVIEW.
RX   PubMed=22912627; DOI=10.3389/fmicb.2012.00275;
RA   Arias J.F., Koyama T., Kinomoto M., Tokunaga K.;
RT   "Retroelements versus APOBEC3 family members: No great escape from the
RT   magnificent seven.";
RL   Front. Microbiol. 3:275-275(2012).
RN   [20]
RP   FUNCTION IN HTLV-1 RESTRICTION.
RX   PubMed=22457529; DOI=10.1128/jvi.06570-11;
RA   Ooms M., Krikoni A., Kress A.K., Simon V., Muenk C.;
RT   "APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic
RT   virus type 1.";
RL   J. Virol. 86:6097-6108(2012).
RN   [21]
RP   SUBCELLULAR LOCATION.
RX   PubMed=22915799; DOI=10.1128/jvi.00595-12;
RA   Phalora P.K., Sherer N.M., Wolinsky S.M., Swanson C.M., Malim M.H.;
RT   "HIV-1 replication and APOBEC3 antiviral activity are not regulated by P
RT   bodies.";
RL   J. Virol. 86:11712-11724(2012).
RN   [22]
RP   REVIEW.
RX   PubMed=22001110; DOI=10.1016/j.semcdb.2011.10.004;
RA   Smith H.C., Bennett R.P., Kizilyer A., McDougall W.M., Prohaska K.M.;
RT   "Functions and regulation of the APOBEC family of proteins.";
RL   Semin. Cell Dev. Biol. 23:258-268(2012).
CC   -!- FUNCTION: DNA deaminase (cytidine deaminase) which acts as an inhibitor
CC       of retrovirus replication and retrotransposon mobility via deaminase-
CC       dependent and -independent mechanisms. After the penetration of
CC       retroviral nucleocapsids into target cells of infection and the
CC       initiation of reverse transcription, it can induce the conversion of
CC       cytosine to uracil in the minus-sense single-strand viral DNA, leading
CC       to G-to-A hypermutations in the subsequent plus-strand viral DNA. The
CC       resultant detrimental levels of mutations in the proviral genome, along
CC       with a deamination-independent mechanism that works prior to the
CC       proviral integration, together exert efficient antiretroviral effects
CC       in infected target cells. Selectively targets single-stranded DNA and
CC       does not deaminate double-stranded DNA or single- or double-stranded
CC       RNA. Exhibits antiviral activity against simian immunodeficiency virus
CC       (SIV), hepatitis B virus (HBV) and human T-cell leukemia virus type 1
CC       (HTLV-1) and may inhibit the mobility of LTR and non-LTR
CC       retrotransposons. {ECO:0000269|PubMed:12859895,
CC       ECO:0000269|PubMed:15466872, ECO:0000269|PubMed:16060832,
CC       ECO:0000269|PubMed:16527742, ECO:0000269|PubMed:20062055,
CC       ECO:0000269|PubMed:22457529}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 2'-deoxycytidine in single-stranded DNA + H(+) + H2O = a 2'-
CC         deoxyuridine in single-stranded DNA + NH4(+); Xref=Rhea:RHEA:50948,
CC         Rhea:RHEA-COMP:12846, Rhea:RHEA-COMP:12847, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:28938, ChEBI:CHEBI:85452,
CC         ChEBI:CHEBI:133902; EC=3.5.4.38;
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC   -!- SUBUNIT: Homodimer. Interacts with APOBEC3G. Does not interact with
CC       APOBEC1. {ECO:0000269|PubMed:11863358}.
CC   -!- INTERACTION:
CC       Q9UH17; P11802: CDK4; NbExp=9; IntAct=EBI-2967317, EBI-295644;
CC       Q9UH17-2; O95994: AGR2; NbExp=3; IntAct=EBI-17624977, EBI-712648;
CC       Q9UH17-2; Q12982: BNIP2; NbExp=3; IntAct=EBI-17624977, EBI-752094;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:16699599,
CC       ECO:0000269|PubMed:18667511, ECO:0000269|PubMed:21835787,
CC       ECO:0000269|PubMed:22915799}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9UH17-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UH17-2; Sequence=VSP_009802;
CC       Name=3;
CC         IsoId=Q9UH17-3; Sequence=VSP_044900;
CC   -!- TISSUE SPECIFICITY: Expressed at high and moderate levels in peripheral
CC       blood leukocytes, spleen, testes, heart, thymus, prostate and ovary.
CC       Also expressed at low levels in several other tissues.
CC       {ECO:0000269|PubMed:11863358, ECO:0000269|PubMed:20308164}.
CC   -!- INDUCTION: Phorbol 12-myristate 13-acetate (PMA) induces overexpression
CC       in keratinocytes. Up-regulated by IFN-alpha.
CC       {ECO:0000269|PubMed:10469298}.
CC   -!- DOMAIN: The CMP/dCMP deaminase domain 1 mediates RNA binding, RNA-
CC       dependent oligomerization and virion incorporation whereas the CMP/dCMP
CC       deaminase domain 2 confers deoxycytidine deaminase activity and
CC       substrate sequence specificity. {ECO:0000269|PubMed:17020885}.
CC   -!- MISCELLANEOUS: It is one of seven related genes or pseudogenes found in
CC       a cluster, thought to result from gene duplication, on chromosome 22.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be due to a competing donor splice
CC       site. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the cytidine and deoxycytidylate deaminase
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD00089.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAD00090.1; Type=Frameshift; Note=Frameshifts result in two separate ORFs termed phorbolins 2 and 3.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U61083; AAD00089.1; ALT_INIT; mRNA.
DR   EMBL; U61084; AAD00090.1; ALT_FRAME; mRNA.
DR   EMBL; AY743217; AAW31743.1; -; mRNA.
DR   EMBL; CT841510; CAJ86440.1; -; mRNA.
DR   EMBL; AL022318; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC053859; AAH53859.1; -; mRNA.
DR   CCDS; CCDS13982.1; -. [Q9UH17-1]
DR   CCDS; CCDS58807.1; -. [Q9UH17-3]
DR   RefSeq; NP_001257340.1; NM_001270411.1. [Q9UH17-3]
DR   RefSeq; NP_004891.4; NM_004900.4. [Q9UH17-1]
DR   PDB; 2NBQ; NMR; -; A=187-382.
DR   PDB; 5CQD; X-ray; 2.08 A; A/C=187-378.
DR   PDB; 5CQH; X-ray; 1.73 A; A=187-378.
DR   PDB; 5CQI; X-ray; 1.68 A; A=187-378.
DR   PDB; 5CQK; X-ray; 1.88 A; A=187-378.
DR   PDB; 5SXG; X-ray; 1.93 A; A/B=191-378.
DR   PDB; 5SXH; X-ray; 1.78 A; A/B=191-378.
DR   PDB; 5TD5; X-ray; 1.72 A; A=187-378.
DR   PDB; 5TKM; X-ray; 1.90 A; A/B=1-191.
DR   PDB; 6NFK; X-ray; 1.86 A; A=187-378.
DR   PDB; 6NFL; X-ray; 1.73 A; A=187-378.
DR   PDB; 6NFM; X-ray; 2.53 A; A=187-378.
DR   PDB; 7RW6; EM; 2.55 A; B/D=193-382.
DR   PDBsum; 2NBQ; -.
DR   PDBsum; 5CQD; -.
DR   PDBsum; 5CQH; -.
DR   PDBsum; 5CQI; -.
DR   PDBsum; 5CQK; -.
DR   PDBsum; 5SXG; -.
DR   PDBsum; 5SXH; -.
DR   PDBsum; 5TD5; -.
DR   PDBsum; 5TKM; -.
DR   PDBsum; 6NFK; -.
DR   PDBsum; 6NFL; -.
DR   PDBsum; 6NFM; -.
DR   PDBsum; 7RW6; -.
DR   AlphaFoldDB; Q9UH17; -.
DR   SMR; Q9UH17; -.
DR   BioGRID; 114950; 142.
DR   IntAct; Q9UH17; 29.
DR   MINT; Q9UH17; -.
DR   STRING; 9606.ENSP00000327459; -.
DR   ChEMBL; CHEMBL4523487; -.
DR   GlyGen; Q9UH17; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9UH17; -.
DR   PhosphoSitePlus; Q9UH17; -.
DR   SwissPalm; Q9UH17; -.
DR   BioMuta; APOBEC3B; -.
DR   DMDM; 12643884; -.
DR   EPD; Q9UH17; -.
DR   jPOST; Q9UH17; -.
DR   MassIVE; Q9UH17; -.
DR   MaxQB; Q9UH17; -.
DR   PaxDb; Q9UH17; -.
DR   PeptideAtlas; Q9UH17; -.
DR   ProteomicsDB; 2630; -.
DR   ProteomicsDB; 84274; -. [Q9UH17-1]
DR   ProteomicsDB; 84275; -. [Q9UH17-2]
DR   ABCD; Q9UH17; 1 sequenced antibody.
DR   Antibodypedia; 35027; 184 antibodies from 29 providers.
DR   DNASU; 9582; -.
DR   Ensembl; ENST00000333467.4; ENSP00000327459.3; ENSG00000179750.16. [Q9UH17-1]
DR   Ensembl; ENST00000335760.9; ENSP00000338897.5; ENSG00000179750.16. [Q9UH17-2]
DR   Ensembl; ENST00000407298.7; ENSP00000385068.3; ENSG00000179750.16. [Q9UH17-3]
DR   GeneID; 9582; -.
DR   KEGG; hsa:9582; -.
DR   MANE-Select; ENST00000333467.4; ENSP00000327459.3; NM_004900.5; NP_004891.5.
DR   UCSC; uc003awo.3; human. [Q9UH17-1]
DR   AGR; HGNC:17352; -.
DR   CTD; 9582; -.
DR   DisGeNET; 9582; -.
DR   GeneCards; APOBEC3B; -.
DR   HGNC; HGNC:17352; APOBEC3B.
DR   HPA; ENSG00000179750; Tissue enhanced (bone marrow, intestine).
DR   MIM; 607110; gene.
DR   neXtProt; NX_Q9UH17; -.
DR   OpenTargets; ENSG00000179750; -.
DR   PharmGKB; PA24892; -.
DR   VEuPathDB; HostDB:ENSG00000179750; -.
DR   eggNOG; KOG4075; Eukaryota.
DR   GeneTree; ENSGT00940000164701; -.
DR   HOGENOM; CLU_047918_0_0_1; -.
DR   InParanoid; Q9UH17; -.
DR   OMA; LCHKVEL; -.
DR   OrthoDB; 5355962at2759; -.
DR   PhylomeDB; Q9UH17; -.
DR   TreeFam; TF331356; -.
DR   BRENDA; 3.5.4.38; 2681.
DR   PathwayCommons; Q9UH17; -.
DR   Reactome; R-HSA-72200; mRNA Editing: C to U Conversion.
DR   Reactome; R-HSA-75094; Formation of the Editosome.
DR   SignaLink; Q9UH17; -.
DR   SIGNOR; Q9UH17; -.
DR   BioGRID-ORCS; 9582; 12 hits in 1155 CRISPR screens.
DR   ChiTaRS; APOBEC3B; human.
DR   GeneWiki; APOBEC3B; -.
DR   GenomeRNAi; 9582; -.
DR   Pharos; Q9UH17; Tbio.
DR   PRO; PR:Q9UH17; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   RNAct; Q9UH17; protein.
DR   Bgee; ENSG00000179750; Expressed in mucosa of transverse colon and 90 other tissues.
DR   ExpressionAtlas; Q9UH17; baseline and differential.
DR   Genevisible; Q9UH17; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000932; C:P-body; IBA:GO_Central.
DR   GO; GO:0004126; F:cytidine deaminase activity; IBA:GO_Central.
DR   GO; GO:0047844; F:deoxycytidine deaminase activity; IMP:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0016554; P:cytidine to uridine editing; IBA:GO_Central.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0070383; P:DNA cytosine deamination; IBA:GO_Central.
DR   GO; GO:0080111; P:DNA demethylation; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0045869; P:negative regulation of single stranded viral RNA replication via double stranded DNA intermediate; IBA:GO_Central.
DR   GO; GO:0010529; P:negative regulation of transposition; IDA:UniProtKB.
DR   GO; GO:0010526; P:retrotransposon silencing; IDA:UniProtKB.
DR   CDD; cd01283; cytidine_deaminase; 1.
DR   Gene3D; 3.40.140.10; Cytidine Deaminase, domain 2; 2.
DR   InterPro; IPR016192; APOBEC/CMP_deaminase_Zn-bd.
DR   InterPro; IPR002125; CMP_dCMP_dom.
DR   InterPro; IPR016193; Cytidine_deaminase-like.
DR   PANTHER; PTHR13857:SF39; DNA DC-DU-EDITING ENZYME APOBEC-3A-RELATED; 1.
DR   PANTHER; PTHR13857; MRNA EDITING ENZYME; 1.
DR   Pfam; PF18782; NAD2; 2.
DR   SUPFAM; SSF53927; Cytidine deaminase-like; 2.
DR   PROSITE; PS00903; CYT_DCMP_DEAMINASES_1; 2.
DR   PROSITE; PS51747; CYT_DCMP_DEAMINASES_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Antiviral defense; Hydrolase; Immunity;
KW   Innate immunity; Metal-binding; Nucleus; Reference proteome; Repeat;
KW   RNA-binding; Zinc.
FT   CHAIN           1..382
FT                   /note="DNA dC->dU-editing enzyme APOBEC-3B"
FT                   /id="PRO_0000171753"
FT   DOMAIN          29..138
FT                   /note="CMP/dCMP-type deaminase 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01083"
FT   DOMAIN          210..326
FT                   /note="CMP/dCMP-type deaminase 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01083"
FT   ACT_SITE        255
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000255"
FT   BINDING         66
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         97
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         100
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         253
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         284
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   BINDING         289
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         191..382
FT                   /note="YLMDPDTFTFNFNNDPLVLRRRQTYLCYEVERLDNGTWVLMDQHMGFLCNEA
FT                   KNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENT
FT                   HVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPWD
FT                   GLEEHSQALSGRLRAILQNQGN -> LRIFSVAFTAAMRSCASWTWFLLCSWTRPRSTG
FT                   SLGSSPGAPASPGAVPGKCVRSFRRTHT (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_009802"
FT   VAR_SEQ         242..266
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15461802"
FT                   /id="VSP_044900"
FT   VARIANT         62
FT                   /note="K -> E (in dbSNP:rs2076109)"
FT                   /evidence="ECO:0000269|PubMed:15461802"
FT                   /id="VAR_018142"
FT   VARIANT         98
FT                   /note="P -> L (in dbSNP:rs2076110)"
FT                   /id="VAR_018143"
FT   VARIANT         109
FT                   /note="S -> A (in dbSNP:rs17000697)"
FT                   /id="VAR_033455"
FT   VARIANT         146
FT                   /note="T -> K (in dbSNP:rs5995649)"
FT                   /evidence="ECO:0000269|PubMed:10469298,
FT                   ECO:0000269|PubMed:15461802, ECO:0000269|PubMed:15489334"
FT                   /id="VAR_018144"
FT   VARIANT         351
FT                   /note="R -> H (in dbSNP:rs1053813)"
FT                   /id="VAR_048722"
FT   CONFLICT        103..104
FT                   /note="KL -> NV (in Ref. 1; AAD00090)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        227..228
FT                   /note="TW -> WM (in Ref. 1; AAD00089)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        255..256
FT                   /note="EL -> DW (in Ref. 1; AAD00089)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        306
FT                   /note="R -> P (in Ref. 1; AAD00089)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        356
FT                   /note="F -> S (in Ref. 2; AAW31743)"
FT                   /evidence="ECO:0000305"
FT   HELIX           14..21
FT                   /evidence="ECO:0007829|PDB:5TKM"
FT   STRAND          32..43
FT                   /evidence="ECO:0007829|PDB:5TKM"
FT   STRAND          46..61
FT                   /evidence="ECO:0007829|PDB:5TKM"
FT   HELIX           63..65
FT                   /evidence="ECO:0007829|PDB:5TKM"
FT   HELIX           67..78
FT                   /evidence="ECO:0007829|PDB:5TKM"
FT   STRAND          86..94
FT                   /evidence="ECO:0007829|PDB:5TKM"
FT   HELIX           98..110
FT                   /evidence="ECO:0007829|PDB:5TKM"
FT   STRAND          114..122
FT                   /evidence="ECO:0007829|PDB:5TKM"
FT   HELIX           128..131
FT                   /evidence="ECO:0007829|PDB:5TKM"
FT   HELIX           134..140
FT                   /evidence="ECO:0007829|PDB:5TKM"
FT   STRAND          144..147
FT                   /evidence="ECO:0007829|PDB:5TKM"
FT   HELIX           150..160
FT                   /evidence="ECO:0007829|PDB:5TKM"
FT   HELIX           174..188
FT                   /evidence="ECO:0007829|PDB:5TKM"
FT   HELIX           195..202
FT                   /evidence="ECO:0007829|PDB:5CQI"
FT   HELIX           206..208
FT                   /evidence="ECO:0007829|PDB:7RW6"
FT   STRAND          215..224
FT                   /evidence="ECO:0007829|PDB:5CQI"
FT   STRAND          227..230
FT                   /evidence="ECO:0007829|PDB:5CQI"
FT   HELIX           232..234
FT                   /evidence="ECO:0007829|PDB:5CQI"
FT   STRAND          236..239
FT                   /evidence="ECO:0007829|PDB:5CQI"
FT   HELIX           245..247
FT                   /evidence="ECO:0007829|PDB:2NBQ"
FT   HELIX           254..261
FT                   /evidence="ECO:0007829|PDB:5CQI"
FT   HELIX           262..265
FT                   /evidence="ECO:0007829|PDB:5CQI"
FT   STRAND          269..271
FT                   /evidence="ECO:0007829|PDB:2NBQ"
FT   STRAND          273..281
FT                   /evidence="ECO:0007829|PDB:5CQI"
FT   HELIX           289..299
FT                   /evidence="ECO:0007829|PDB:5CQI"
FT   TURN            300..302
FT                   /evidence="ECO:0007829|PDB:2NBQ"
FT   STRAND          303..311
FT                   /evidence="ECO:0007829|PDB:5CQI"
FT   HELIX           319..328
FT                   /evidence="ECO:0007829|PDB:5CQI"
FT   STRAND          332..335
FT                   /evidence="ECO:0007829|PDB:5CQI"
FT   HELIX           338..348
FT                   /evidence="ECO:0007829|PDB:5CQI"
FT   HELIX           362..377
FT                   /evidence="ECO:0007829|PDB:5CQI"
SQ   SEQUENCE   382 AA;  45924 MW;  DA6EDD23E8856240 CRC64;
     MNPQIRNPME RMYRDTFYDN FENEPILYGR SYTWLCYEVK IKRGRSNLLW DTGVFRGQVY
     FKPQYHAEMC FLSWFCGNQL PAYKCFQITW FVSWTPCPDC VAKLAEFLSE HPNVTLTISA
     ARLYYYWERD YRRALCRLSQ AGARVTIMDY EEFAYCWENF VYNEGQQFMP WYKFDENYAF
     LHRTLKEILR YLMDPDTFTF NFNNDPLVLR RRQTYLCYEV ERLDNGTWVL MDQHMGFLCN
     EAKNLLCGFY GRHAELRFLD LVPSLQLDPA QIYRVTWFIS WSPCFSWGCA GEVRAFLQEN
     THVRLRIFAA RIYDYDPLYK EALQMLRDAG AQVSIMTYDE FEYCWDTFVY RQGCPFQPWD
     GLEEHSQALS GRLRAILQNQ GN
//
